Denali Therapeutics (NASDAQ:DNLI) Stock Price Down 4.3% - Time to Sell?

Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report)'s stock price traded down 4.3% during trading on Friday . The company traded as low as $22.47 and last traded at $22.28. 55,862 shares changed hands during mid-day trading, a decline of 95% from the average session volume of 1,057,344 shares. The stock had previously closed at $23.28.

Analyst Ratings Changes

Several research firms have commented on DNLI. JPMorgan Chase & Co. lowered their target price on shares of Denali Therapeutics from $28.00 to $24.00 and set an "overweight" rating on the stock in a research report on Tuesday, January 7th. Baird R W raised Denali Therapeutics to a "strong-buy" rating in a research note on Tuesday, January 7th. HC Wainwright decreased their target price on Denali Therapeutics from $90.00 to $87.00 and set a "buy" rating for the company in a research report on Tuesday, January 7th. Cantor Fitzgerald downgraded Denali Therapeutics from an "overweight" rating to a "neutral" rating in a report on Monday, October 7th. Finally, Raymond James restated a "market perform" rating on shares of Denali Therapeutics in a research note on Thursday, October 10th. Two analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $38.91.

Denali Therapeutics Stock Performance

The stock has a 50-day moving average of $22.52 and a 200 day moving average of $24.82. The firm has a market capitalization of $3.20 billion, a P/E ratio of -8.05 and a beta of 1.39.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.03). During the same period in the previous year, the company earned ($0.72) EPS. On average, equities analysts predict that Denali Therapeutics Inc. will post -2.73 EPS for the current year.

Insider Buying and Selling

In other news, Director Vicki L. Sato sold 1,020 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $30.00, for a total value of $30,600.00. Following the transaction, the director now owns 111,056 shares of the company's stock, valued at $3,331,680. This represents a 0.91 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Alexander O. Schuth sold 15,558 shares of the firm's stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $29.91, for a total value of $465,339.78. Following the completion of the transaction, the insider now owns 178,066 shares in the company, valued at $5,325,954.06. This represents a 8.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 64,518 shares of company stock worth $1,469,382 over the last three months. 7.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Denali Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in DNLI. CWM LLC raised its holdings in Denali Therapeutics by 43.6% during the 3rd quarter. CWM LLC now owns 2,153 shares of the company's stock worth $63,000 after buying an additional 654 shares during the period. Quest Partners LLC bought a new stake in shares of Denali Therapeutics during the third quarter worth $73,000. Assetmark Inc. raised its holdings in shares of Denali Therapeutics by 18.0% during the third quarter. Assetmark Inc. now owns 3,808 shares of the company's stock worth $111,000 after acquiring an additional 580 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in Denali Therapeutics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company's stock valued at $152,000 after acquiring an additional 920 shares in the last quarter. Finally, KBC Group NV boosted its stake in Denali Therapeutics by 75.8% in the 4th quarter. KBC Group NV now owns 6,334 shares of the company's stock worth $129,000 after purchasing an additional 2,731 shares during the period. 92.92% of the stock is owned by institutional investors.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.